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ABSTRACT
This thesis reviews the developments in the research of business power and social structure, particularly focusing on
the phenomena of "inner circle" and "structural hole" and their underlying theories. Through a close study on its
technical and commercial developments as well as its ethical controversies, the American stem cell industry is found
to be an interesting area to carry out the power structure research. Increasing political intervention and declining
profitability make the American stem cell industry highly analogous to the entire American corporate community in
1970s and early 1980s when business inner circle first emerged. Meanwhile, the American stem cell industry also
differs from the social context of a typical inner circle in a number of ways, which means special research strategy is
required for the study on stem cell inner circle. Such analogue with slight deviation brings excitement to the power
structure research in this highly entrepreneurial yet tightly regulated industry.
12 U.S. stem cell companies that well represent the American stem cell industry are selected to form a sampling for
this power structure study. Stem cell inner circle is defined in this thesis as a group of people who are playing critical
roles in the stem-cell related scientific, commercial, governmental activities. In search for this inner circle,
definitions are given to the stem-cell related scientific, commercial and governmental activities to first identify people
who are important individuals in the scientific, commercial and governmental circles respectively. By overlapping
those three circles, a group of people in the intersection, termed the "stem cell inner circle", are identified. The
formation of such an inner circle is then empiristically explained with the theory of "structural hole", especially the
brokerage mechanism, based on the unique academic, commercial and political characteristics of the American stem
cell industry. Finally, a number of possible topics for future researches that can be built on this thesis are suggested.
Thesis Supervisor: Fiona Murray
Title: Assistant Professor of Management of Technology, Innovation, and Entrepreneurship
Assistant Professor, Harvard-MIT Division of Health Sciences and Technology
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EXECUTIVE SUMMARY
Stem cells are the basic building blocks of the human body. These cells can self-renew
indefinitely and also differentiate into more mature cells with specialized functions.
Importantly, these cells are research tools and they open many doors of opportunity for
biomedical research. The unique capability of stem cells to differentiate into mature
cells gives hope to new transplantation and therapeutic research to restore vital body
functions.
Today, we have reached an era where science is on the brink of understanding and
controlling individual cell growth and manipulation and have come head to head with
some hotly contested human ethical issues. And nowhere is this debate more apparent
in the new field of stem cell research. The majority of ethical debates are centered on
embryonic stem cells because to some people, the research that necessitates the
destruction of a human embryo is regarded morally abhorrent. Although most
bio-ethics experts have agreed that using leftover embryos that were originally created for
reproductive purposes is indeed ethical (National Research Council 2001), the current
public policy in the US is still hampering the basic stem cell research through limited
federal research grants and stringent application requirements for those grants.
Rigorous regulations on stem cell research also compel corporation funds to go overseas
to research labs in countries with more stem cell friendly policies. The downturn of
stock market and overall social economy further drains the private funding from the stem
cell industry. The momentum and prosperity gained from many blockbuster scientific
findings have started fading away since then.
Inner circles emerged in the American corporate world during the period of 1970s and
early 1980s when most large U.S. companies were experiencing declining profitability.
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During the same period of time, over-involvement of government in business via more
rigorous industry-specific regulations gave more coherence to the business circle most
actively opposed to it. In this sense, the strictly regulated stem cell industry with
shrinking investment and profitability highly resembles the entire American business in
1970s and early 1980s. This provides a perfect background setup for the emergence of
the stem cell inner circle. The observation of cross-functional multi-appointments, or
"interlocking directorships", of some stem cell elite across all scientific, commercial and
governmental worlds further increases the possibility of the existence of such a circle.
In addition, the connections the elite have built across different domains in the stem cell
field offers an excellent context for conducting social capital research, more specifically,
research about the brokerage mechanism over the structural holes present between those
different domains.
Unlike the traditional inner circle, this thesis defines the "stem cell inner circle" as the
group of people who are playing most active roles in stem cell related scientific,
commercial and governmental activities rather than just in the business circle alone.
Therefore, the research strategy for the stem cell inner circle goes beyond the 3x3
classification used in the traditional network analysis for classic inter-corporate relations.
In addition, the unit of analysis for the stem cell inner circle is domain instead of sector.
Domains in question include scientific domain, commercial domain and governmental
domain in three dimensions and go well beyond the only dimension, business dimension,
in a traditional inner circle context.
12 U.S. stem cell companies are selected to form a sampling for the stem cell inner circle
study. All of these firms are actively pursuing ways to cure afflictions like spinal cord
injury, Parkinson's and Alzheimer's by devoting a significant part of their research and
commercial efforts to the area of neural stem cells. Moreover, the commercial activities
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of the sample firms, represented by their patent filing behaviors, perfectly epitomize the
ups and downs of the American stem cell industry.
Stem cell people who are playing active roles in the scientific domain are defined in this
thesis as scientists whose names appear in NIH Stem Cell Report, NAS Stem Cell Report
or stem cell papers in Tissue Engineering with high citation frequencies. Active
participants of the stem cell commercial activities are defined as the group of people who
not only are founders or Scientific Advisory Board members of one or more sample stem
cell firms, but also have co-published papers or filed patents with the firms on stem cell
topics. The governmental involvement of the stem cell inner circle is defined to include
federal-level testimonies about research on stem cell and human embryos, and the
appointment or membership in various NIH National Advisory Councils and NIH Stem
Cell Taskforce and Working Groups that regulate the stem cell industry.
Finally, the result of this research verifies the existence of a non-traditional inner circle
brokering the flow of information between any of the three domains in the stem cell
industry. Overlapping the three pools of people who are backbones respectively in stem
cell related scientific, commercial and governmental activities generates a core group of 5
people who are most devoted to all those three domains. Beyond the scope of the 12
sample stem cell firms, a larger and more complete inner circle can be expected.
Members of the inner circle all hold cross-domain interlocking directorships and are
closely connected to each other across all the scientific, commercial and governmental
aspects of the stem cell field. While the above evidence serves as a perfect grounding
for the stem cell inner circle to realize collective actions and advocate for a more relaxed
political environment, how a unified vision is achieved and mutual concerns are shared in
the circle and whether bridging the structural holes between scientific, commercial and
governmental domains really produce financial benefits to relevant stem cell firms are yet
11
to be explored in future researches.
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CHAPTER 1: INTRODUCTION
Former U.S. President Ronald Reagan's recent demise brought to the nation not only
grief and sadness, but also more attention on stem cell research, which holds the gigantic
potential to cure Alzheimer's, the illness that ravaged the former President for more than
10 years until his death, and a long list of other afflictions.
Stem cells are unspecialized cells that can self-renew indefinitely and also differentiate
into more mature cells with specialized functions (National Research Council 2001).
Thanks to their self-replication and differentiation abilities, stem cells offer
unprecedented opportunities for developing regenerative medicines and new medical
therapies for debilitating diseases like diabetes, degenerative neurological diseases, brain
and spinal cord injury as well as provide a new way to explore fundamental questions of
biology such as mechanisms of cell differentiation, growth, and death. However, the
embryonic stem cell research incurs opposition on the ethical, moral and religious
grounds in that such research deprives a human embryo of any further potential to
develop into a complete human being.
Because of the cutting-edge technology stem cell research requires and the ethical
dilemma it encounters concurrently, the stem cell industry is a very unique one - it is
extremely entrepreneurial yet at the same time highly regulated. Given the fact that the
cell therapy industry is still in its infancy stage and demands large amount of basic
research, a large number of stem cell firms are start-ups founded by key scientists in the
stem cell field who usually have strong affiliations with universities or other research
institutions. As a result of the controversial nature of the stem cell research, there have
been considerable amount of governmental intervention that seriously limit the
development and commercialization of the stem cell products.
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Due to the special characteristics of stem cell industry, it becomes increasingly interesting
to see how the academic celebrities shift their roles and become frequently engaged in
commercial and governmental activities to strive for their firms' successes. This thesis
focuses on the search for a "stem cell inner circle" which is composed of scientists who
are actively participating in stem cell related scientific, commercial and governmental
activities and then try to explain some of the phenomena observed in the stem cell
industry with the principles of economic sociology in the Social Capital metaphor,
especially the brokerage mechanism and structural holes theory (Burt 2000), and with the
Power Structure research, especially the "inner circle" theory (Useem 1984).
14
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CHAPTER 2: LITERATURE REVIEW AND HYPOTHESIS
2.1 Power Structure Research - Inner Circle
Power structure research is an approach to the study of power that highlights the unequal
distribution of resources, such as wealth, political office and control of the mass media,
upon which power is based, and the importance of formal and informal social networks
as the means by which power is concentrated and institutionalized. Modern power
structure research has its roots in the radical social movements during the 1960s and
1970s. Building upon the pioneering work of sociologists like Floyd Hunter and C.
Wright Mills, radical scholars of the era sought to debunk the prevailing myths about
American democracy and to advance an alternative view of power in America.
The most important and widely read early work of power structure research was Who
Rules America, published by G William Domhoff in 1967, where he finds "persuasive
evidence for the existence of a socially cohesive national upper class." (Domhoff 1967)
These "higher circles", composed mainly of corporate executives, primary owners and
their descendents, constitute, in the author's view, "the governing class in America", for
these businesspeople and their families to dominate the top positions of government
agencies, the political parties, and the governing boards of nonprofit organizations.
Ralph Miliband (1969) reaches a similar concluding finding that "elite pluralism does not
prevent the separate elites in capitalist society from constituting a dominant economic
class, possessed of a high degree of cohesion and solidarity, with common interests and
common purposes which far transcend their specific differences and disagreements."
The business enterprise has for long been an important topic for the power structure
research, for its organization and operation are central to the structure of a capitalist
15
industrial society, forming the basis of both the class structure and wider power relations.
Scott (1991) generalizes that power in inter-corporate networks is based on at least three
distinct kinds of inter-corporate relations: personal, capital and commercial. Personal
relations are those links between agents involve direct connections between people, or
that involve the sharing or exchange of personnel. Capital relations are the links
between business agents that result from shareholdings and from the granting or
withholding of credits. Commercial relations involve the trading links that arise through
the normal buying and selling of goods and services on the market.
Each of these types of relation can be studies at any one of three levels of analysis:
people, enterprise, or sectors. Where people are taken as the unit of analysis between
which relations are imputed, the research strategy is concerned with such things as the
formation of families and kinship groups and other kinds of solidaristic and cohesive
groups. When the focus of attention is on enterprises, the researcher will be interested
in the ways in which inter-corporate relations lead to the formation of cartels and
coalitions. At a more complex level of analysis, the unit of analysis may be the sector,
when particular areas of activity such as product markets or industries are of interest.
Research may thus be concerned with any one of three types of relation and can involve
any one of three units of analysis. A cross-classification of these two dimensions (Table
1) shows the existence of nine distinct research strategies in the analysis of
inter-corporate relations. The unit-of-analysis dimension in this typology is closely
connected with some of the ideas in Burt's (1980) influential typology of concepts of
network structure. In this thesis, we will focus on personal relations so as to introduce
the inner circle metaphor that follows.
Table 1: Research Strategies for Inter-corporate Networks (Scott 1991)
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Research on personal relations, then, can take people, enterprises, or sectors as its unit of
analysis, each being associated with a distinct strategy of research. Research using
Strategy 1 would concern the informal interpersonal relations that arise through business
activities, and a major interest would be to unveil what these linked individuals may have
in common besides their shared involvement in a particular enterprise or group of
enterprises. On the other hand, the groups of enterprises themselves are central in
research based on Strategy 4. Research using Strategy 7 extends this concern with
interpersonal connections might contribute to the cohesion or segmentation of classes or
elites.
The units of personal relations Scott introduced coincided with the principles of social
organization which Useem (1980) considered are of overriding importance. Among
those are upper-class principle, corporate principle and class-wide principle. Each
contains a fundamentally different implication for the ways in which business enters the
political arena.
The upper-class principles asserts that the first and foremost defining element is a social
network of established wealthy families, sharing a distinct culture, occupying a common
social status, and unified through intermarriage and common experience in exclusive
settings, ranging from boarding schools to private clubs. Domhoff's (1967) work
mentioned earlier about America's "upper-social class", Baltzell's studies of national and
17
Type of Relations
Unit of Analysis Personal Capital Commercial
People 1 2 3
Enterprises 4 5 6
Sectors 7 8 9
metropolitan "business aristocracies" and Collins's treatment of the pre-eminence of
upper-class cultural dominance in America all fall into the category of exploring the
upper-class principles of social organization using Strategy 1 identified in Table 1.
The corporate principle suggests by contrast that the primary defining element is the
corporation itself. Location is determined by the individual's responsibilities in the firm
and the firm's position in the economy. Research of the corporate principle uses
Strategy 4, focusing on groups of companies formed through intersecting personal
relations. Cliques and clusters formed by means of interlocking directorships, etc. earn
considerable attention (Allen 1978, Mintz & Schwartz 1983).
The class-wide principle resides on still different premises about the main elements
defining the social organization of the corporate community. In this framework,
location is primarily determined by position in a set of interrelated, quasi-autonomous
networks encompassing virtually all large corporations. Acquaintanceship circles,
interlocking directorates, webs of inter-firm ownership, and major business associations
are among the central strands of these networks. Using Strategy 7, research of the
class-wide principle looks more generally at issues of class cohesion and the formation of
a corporate elite and an inner circle (Useem 1984, Ratcliff 1987). This
conceptualization of multiple directors as an inner circle originated in Zeitlin's (1974)
work formalizing the insight of early Congressional inquiries.
Research in business power and corporate elite has largely been structured by a debate
over the "managerial revolution" (Berle & Means 1932). The debate is concerned with
changing patterns of ownership and control in the modern enterprise and their
implications for business behavior. If the enterprise changes, patterns of class and
power will change too (Scott 1985). But attention has recently shifted from the structure
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of individual enterprises to the social relations that exist between enterprises. This
newer research emphasizes the social networks in which enterprises are embedded, and
the importance of viewing these networks as arenas of power. Beginning with the
path-breaking articles of Zeitlin & Ratcliff (1974) and Benson (1975), interest has grown
in the study of inter-organizational relations (Nystrom & Starbuck 1981, Aldrich 1979,
Meyer & Scott 1983).
The study of interlocking directorships is at the center of this reorientation. An
interlocking directorship exists when a particular individual sits on two or more corporate
boards. The boards of large enterprises include both internal executives and outside
non-executives among their members. The outside directors include a number of public
and political figures. And some outside directors will hold two, three or even more
outside directorships. Many of these people hold only outside directorships, but others
are internal executive offices of companies in which they have their principal business
interest (Scott 1991). Their directorships spread throughout the economy, and they form
a corporate or business elite, an "inner circle" of corporate decision-makers with power
and influence across the business system as a whole, which, in Useem's work (1984), is
described to be an active group of people in expanding the corporate political activities
through direct subvention of candidates, informal lobbying at the highest levels of
government, or formal access to governmental decision make processes through
numerous business-dominated panels created to advise government agencies and
ministries. When less divided and better organized for collective action, these inner
circle people can be very effective in finding and promoting their shared concerns.
The presence of the same director on two or more boards creates a social relation
between the two enterprises and the simultaneous occupancy of multiple company boards
by the members of the inner circle creates a complex web of social relations.
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Executives with ties to several, often disparate, companies necessarily become concerned
with the joint welfare of the several companies. Their indirect ties to other firms
through the interlocking directorate further enlarge the scope of their concern. Zeitlin
(1974) believes that those who site at the center of this inner circle must have an outlook
and executive policies that conform to the general interests of the corporate community
while still serving particular and narrower interests. As a result, those with multiple
corporate connections are expected not only to share a vision distinct from that of other
business leaders, but also to take a far more active role in promoting their politics. The
inner circle's multiple company connections, degree of social cohesion among the
business elite, close ties with the traditional upper class and pervasive presence among
the leadership positions of the main business associations well facilitate its political
expression (Useem 1984).
With a power supported by so many reinforcing strands of corporate, social, associational
and class connections, the inner circle should be expected to be found at the forefront of
business political outreach. From the standpoint of the government and other
institutions, the multiple-director network is an appealing source of counsel. Although
the patterns are not identical at the national and regional levels, inner circle's four distinct
forms of national political intervention can be drawn analogously from Ratcliff's (1980)
study focusing on the St. Louis Metropolitan region. They are: (1) advisory service to
the national government; (2) assistance in the governance of nonprofit organizations; (3)
financial support for political parties and candidates; and (4) appeals through the mass
media for public opinion.
Although the political mobilization results partly from the growing social and economic
interdependencies among large corporations, the willingness and capability of the
corporate community to act has been affected by external events as well. The new
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powers of the transcorporate network are, ironically, the indirect consequence of the
declining powers of individual companies. Increasingly unable to cope separately with
worsening economic and political environments, firms increasingly recognized the need
for joint action (Burt 1984). During 1970s and early 1980s, when the inner circle first
emerged in the American corporate community, companies encountered challenges
coming from two fundamentally different directions. One was economic - firms
experienced decline of profitability, while the other is political - consumer activism and
federal regulation became the hostile forces around which the ranks of American business
closed. These critical challenges to the power and position of business have added new
elements of class-wide unity.
2.2 Social Capital - Structural Holes
Society can be viewed as a market in which people exchange all variety of goods and
ideas in pursuit of their interests. Certain people or certain groups of people do better in
the sense of receiving higher returns to their efforts. The human capital explanation of
this inequality is that the people who do better are more able individuals, while the social
capital metaphor is that the people who do better are somehow better connected. The
same conclusion can be derived from diverse styles of argument (Coleman 1990;
Bourdieu and Wacquant 1992; Burt 1992; Putnam 1993) that social capital is a kind of
capital that can create for certain individuals or groups a competitive advantage in
pursuing their ends. Better connected people enjoy higher returns.
There are four network mechanisms that define social capital in theory: contagion,
prominence, closure and brokerage across structural holes (Burt 2000). The structure of
relationships among people and organizations in a market can affect, or replace,
information. Replacement happens when market information is so ambiguous that
21
people use network structure as the best available information. Such assumption
underlies discussion of network contagion and prominence as social capital. In network
models of contagion, information is not a clear guide to behavior, so observable peer
behavior is taken as a signal of proper behavior. In network models of prominence,
information is not a clear guide to behavior, so the prominence of an individual or group
is taken as a signal of quality or resources (White 1981).
Network contagion and prominence could be studied as social capital, but they are more
often discussed as other concepts. Contagion is more familiar as the mechanism for
imitation in institutional theory (e.g., Strang and Soule 1998) while network prominence
is more often discussed in contemporary economics and sociology as reputation or status.
Therefore, the network mechanisms typically discussed as social capital are closure and
brokerage.
Closure and brokerage both begin with the assumption that communication takes time, so
prior relationships affect who knows what early. Information can be expected to spread
across the people in a market, but it will circulate within groups before it circulates
between groups. A generic research finding is that information circulates more within
than between groups - within a work group more than between groups, within a division
more than between divisions, within an industry more than between industries (Festinger,
Schachter and Back 1950). The result is that people are not simultaneously aware of
opportunities in all groups. Even if information is of high quality, and eventually
reaches everyone, the fact that diffusion requires an interval of time means that
individuals informed early or more broadly have an advantage. A close network in
which everyone is connected such that no one can escape the notice of others creates
advantage by lowering the risk of cooperation (Coleman 1988) in that it (1) improves the
efficiency of information access (Coleman 1990) and (2) facilitates sanctions that make it
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less risky for people in the network to trust one another (Coleman 1988).
While closure creates advantage by lowering the risk of cooperation, network brokerage
creates advantage by increasing the value of cooperation. The weaker connections
between separate groups are holes in the social structure of the market. Burt (1992)
argues that these structural holes create a competitive advantage for individuals whose
networks span the holes. Since people on either side of the structural hole circulate in
different flow of information, structural holes are an opportunity to broker the flow of
information between people and control the projects that bring together people from
opposite sides of the hole. Therefore, there are both information benefits and control
benefits of bridging structural holes at the same time.
Structural holes separate non-redundant sources of information, sources that are more
additive than overlapping. A person who connects separate groups and bridge structural
holes is an entrepreneur in the literal sense - a person who adds value by brokering
connections between others (Burt 1992), for there is no value to a venture if it only
connects people already connected. Her bridge connections to other groups give her an
advantage with respect to information access. First of all, she reaches a higher volume
of information because she reaches more people directly or indirectly. Second, the
diversity of her contacts across a number of separate groups means that her higher
volume of information contains fewer redundant bits of information. Moreover, she is
positioned at the cross-roads of social organization so she is early to learn about activities
in all the groups she connects. Finally, more diverse contacts mean that she is more
likely to be a candidate discussed for inclusion in new opportunities. In addition, there
is a positive feedback loop in which this advantage brings more benefits: her early access
to diverse information makes her more attractive to other people as a contact in their own
network.
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The information benefits make a network entrepreneur more likely to know when it
would be valuable to bring together certain disconnected contacts, which gives him
disproportionate say in whose interests are served when the contacts come together.
Moreover, the holes between his contacts mean that he can broker communication while
displaying different beliefs and identities to each contact (Breiger 1995). Stewart (1990)
argues that bridging roles are based on the recognition of discrepancies of evaluation,
which requires an edge in information about both sides of the bridge. Because this
requires an information network, bridgers will commit time, energy, travel, and
sociability to develop their personal networks. For many entrepreneurs, their most
significant resource is a ramifying personal network and value is created by them
strategically moving accurate, ambiguous, or distorted information between people on
opposite sides of structural holes in the routine flow of information. As a result,
individuals with networks rich in structural holes should have an edge in creativity and
learning and adaptive implementation, and therefore could obtain higher returns to their
efforts (Burt 2000).
2.3 Context Setting and Hypothesis
Many areas of science could have been chosen for power structure and social capital
analyses. The stem cell field is particularly attractive as it not only bears huge potential
for commercialization of the technology, but more importantly, it confronts considerable
regulatory as well as technical challenges today. Cell therapy, which uses stem cells as
regenerative medicine to repair damaged human cells, holds great commercial prospect
for an enormous market composed of hundreds of thousands of patients who suffer from
degenerative diseases, such as Alzheimer's, Parkinson's, diabetes, leukemia, etc.
However, moral and ethical problems arise from the fact that the derivation of human
embryonic stem cells involves the destruction of human embryos. Therefore, to realize
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the promise of stem cells for yielding new medical therapies, the stem cell community
will have to grapple with more than just scientific uncertainties, which are already a big
challenge.
Besides the controversial nature of stem cell research, the stem cell industry has also
shown some suitable conditions for the emergence of inner circles and network
entrepreneurs. First of all, stem cell companies are undergoing profit decline and facing
rigorous policy intervention today in the United States. This is a situation highly
analogous to the entire American corporate community in 1970s and early 1980s. A
single firm does not have the ability to lift or remove the policy constraints and collective
action is an ideal approach to maximize the voice of the stem cell industry as a whole.
Second, since the stem cell industry is still in its infancy stage and demands large amount
of basic research, most of stem cell firms are start-ups founded by entrepreneurial
academics. By connecting two somewhat separated domains in the stem cell field, the
academic world and the commercial world, those scientist-businessmen enjoy both of the
information benefits and control benefits bridging the structural holes could bring them.
Third, same rationale applies to the brokering behavior between the commercial world
and governmental world too. In a highly regulated industry, policy adaptability is
critical for a firm to survive and thrive. The early access to regulatory and legislative
information regarding stem cell research allows a company to quickly respond to policy
changes and find quick solutions to political issues.
What makes the stem cell industry a more interesting area to perform the network
analyses in is that although the stem cell industry shows some excellent potential for
power structure research, it's in fact not the classic context for the inner circle theory.
The difference between the stem cell industry and the classic social setup of inner circle
lies in three factors. First, stem cell firms are usually start-ups while classic inner
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circles reside within the boundary of large corporations. Second, two different types of
inner circles can be predicted to exist in the stem cell industry. Besides the traditional
inner circle which is composed of executives holding interlocking directorates in separate
stem cell companies', there should also exist a group of people who form what I term
"stem cell inner circle". Because of the leading edge technologies they possess and the
policy restrictions they bear, it can be assumed that stem cell companies would want to
develop the links well beyond the mere business world and extend such connections into
the academic and governmental arenas. Therefore, people in the second type of inner
circle, which may overlap with the traditional inner circle, should be playing very active
roles in stem cell related scientific, commercial and governmental activities. Scientific
activities primarily refer to publishing research findings in the stem cell area.
Commercial activities mainly include filing patents and co-publishing papers with stem
cell firms, assuming the Scientific Advisory Board member position in those firms or
even running their own companies. Among governmental activities are sitting on
committees of the government agencies that regulate the stem cell industry, providing
stem cell related testimonies in the Congress and advising federal level policy makers
about stem cell regulations. The second type of inner circle is what this thesis focuses
on. Finally, the research strategy for the second type of inner circle should go beyond
the 3x3 classification illustrated in Table 1. The unit of analysis for the stem cell inner
circle should be domain instead of sector. Domains in question include scientific
domain, commercial domain and governmental domain in three dimensions and go well
beyond the only dimension, business dimension, in a traditional inner circle context.
Based on the close analogue between the American stem cell industry and the historical
social context of inner circle as well as the slight difference between the two, the
l A perfect example of the members in the traditional inner circle in the stem cell field is Dr. Irving
Weissman, a professor of Cancer Biology at Stanford University who founded three stem cell companies -
SyStcmix Inc., Celltrans Inc. and StemCells Inc., the last two of which hce still helps manage.
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hypothesis of this thesis can be put forward as below:
The definition of "an active role" will be given in the Methodology section of the thesis.
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In the current entrepreneurial yet highly regulated stem cell industry, a
stem cell inner circle, which is composed of people that are playing
very active roles in stem-cell related scientific, commercial and
governmental activities, should exist.
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CHAPTER 3: STEM CELLS - HYPES AND HOPES
3.1 Stem Cell Basics
Stem cells are the cells from the embryo, fetus, or adult that have, under certain
conditions, the ability to reproduce themselves for long periods or, in the case of adult
stem cells, throughout the life of the organism (NIH 2001). Serving as a sort of repair
system for the body, they can theoretically divide without limit to replenish other cells as
long as the person or animal is still alive.
Stem cells are crucial for living organisms for many reasons. In an embryo of its early
stage, stem cells in developing tissues give rise to the multiple specialized cell types that
make up the heart, lung, skin, and other tissues. In some adult tissues, such as bone
marrow, muscle, and brain, discrete populations of adult stem cells generate replacements
for cells that are lost through normal wear and tear, injury, or disease.
To be defined as a stem cell, a cell must satisfy several operational criteria. First of all,
it must be clonogenic, capable of unlimited self-renewal by symmetric division.
Secondly, it must be able to divide asymmetrically, one daughter resembling its mother,
the other giving rise to multiple types of differentiated cells representing all three
primitive embryonic germ layers (the ectoderm, mesoderm, and endoderm). Finally, it
must originate from an embryonic or adult stem-cell source, which will be discussed
later.
One way to consider stem cell's replicable functionality is to think about the remarkable
potential of the human body to rebuild itself. Most of us sustain, throughout our lives,
numerous injuries from which we recover spontaneously, sometimes even without
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realized we were hurt. The wound healing processes involve the recruitment and
proliferation of stem cells, which retain a collective memory of how the tissue was first
constructed in order to give rise to the new tissue cells that restore the damaged tissues or
even organs to their original forms and functions.
Although most cells in an animal or human being are committed to fulfilling a single
function in organs like skin or heart, stem cells are uncommitted and remain
undifferentiated until they receive signals to develop into specialized cells. One of the
fundamental properties of a stem cell is that it does not have any tissue-specific structures
that allow it to perform specialized functions. The specific factors and conditions that
allow stem cells to remain unspecialized are of great interest to scientists, who are just
beginning to understand the signals inside and outside cells that trigger stem cell
differentiation. The internal signals are believed to be controlled by a cell's genes,
which are interspersed across long strands of DNA, and carry coded instructions for all
the structures and functions of a cell. The external signals for cell differentiation
include physical contact with neighboring cells, chemicals secreted by other cells and
certain molecules in the microenvironment.
It was presumed, until lately, that those undifferentiated and self-replicating cells
contributed exclusively to the regeneration of the organ in which they reside. Recent
studies have suggested that some stem cells are pluripotent, i.e., they can exhibit
plasticity, the ability to differentiate into specialized cell types beyond those of the tissues
in which they normally reside. When a stem cell divides, each new cell has the potential
to either remain a stem cell or become another type of cell with a more specialized
function. Those multipotent cells were discovered from many tissues of the body, even
from some that have historically been considered incapable of regeneration, such as the
nervous system.
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According to where the cells come from, stem cells can be categorized into three types:
embryonic stem cells are extracted from the inner cell mass of embryos, fetal stem cells
exist in fetuses while adult cells are present in some adult tissues, including brain, spinal
cord, and bone marrow. For a detailed description for each type of the stem cell, please
see Appendix 1.
3.2 The Promise of Stem Cell Research
Because of their remarkable plasticity and pluripotency, human stem cells offer
unprecedented opportunities in at least three research areas. First and foremost, human
stem cells hold the most promising potential to generate cells and tissues that could be
used for cell-based therapies. And so far, embryonic stem cells are believed to be the
key to the increasingly promising area of regenerative medicine, which could profoundly
improve our ability to prevent and cure disease. Second, human stem cells could be
used as surrogate in screening and testing new drugs. And third, studies of human
embryonic stem cells could provide a deeper understanding of cell differentiation and
development, with possible consequences for the treatment of diseases such as cancer as
well as new ways to explore fundamental questions of biology such as mechanisms of
cell growth and death.
Today, donated organs and tissues are often used to replace ailing or destroyed tissue, but
the growing demand for transplantable tissues and organs far outweighs the available
supply. Self-replicable and multipotent, stem cells may hold the key to replacing cells
lost in many devastating diseases and stem cell research could lead to the development of
innovative replacement or transplantation therapies for diseases such as diabetes or heart
disease. In fact, the manipulation of hematopoietic stem cells is already an important
clinical tool and human hematopoietic stem cells have been essential in bone-marrow
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grafts that are in wide clinical use like treating leukemia patients. One of the major
focuses of research today is the use of stem cells to generate replacement tissues for
treating neurological diseases such as spinal cord injury, multiple sclerosis, Parkinson's
disease, and Alzheimer's disease, for which the concept of replacing destroyed or
dysfunctional cells in the brain or spinal cord is a practical goal. Another major
discovery frontier for stem cell research is the development of transplantable pancreatic
tissues that can be used to treat diabetes. Ways to direct specialization of adult and
embryonic stem cells to become pancreatic islet-like cells that can be used to control
blood glucose levels have been vigorously pursued by scientists in the past years and
human embryonic stem has been reported to be directly differentiated into cells that
produce insulin (Lumelsky et al 2001). In addition, although scientists are not so certain
of the identity of the stem cell concerned, skin cells can also be grown in large numbers,
providing a life-saving grafting treatment possibility for burn victims. And the
transplantation of cardiomyocytes that are derived from stem cells into damaged hearts is
becoming an increasingly promising strategy for the treatment of heart disease and the
restoration of heart function.
Testing the candidate therapeutic drugs is another future use of human stem cells and
their derivatives. Although current pharmaceutical research relies mainly on animal
model testing, it cannot always precisely predict the effects that a developmental drug
may have on human cells. New medications could be tested for safety on differentiated
cells generated from human pluripotent cell lines. For example, specialized liver cells
could be developed from stem cells to evaluate drug detoxifying capabilities and
represents a new type of early warning system to prevent adverse reactions in patients.
Moreover, the availability of pluripotent stem cells would allow drug testing in a wider
range of cell types.
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Studies of human embryonic stem cells may also yield information about the complex
events that occur during human development. Most of those events, which can result in
congenital birth defects and placental abnormalities that lead to spontaneous abortion, are
still unexplained. By studying human embryonic stem cells in vitro, it may be possible
to identify the genetic, molecular, and cellular events that cause these problems and
identify methods for avoiding them (Rathjen et al 1998). Also, one primary goal of
stem cell research is to identify how undifferentiated stem cells become specialized as
some of the most serious medical conditions, such as cancer, are due to abnormal cell
division and differentiation. A better understanding of the genetic and molecular
controls of these processes could provide insights into how such diseases arise and
suggest new strategies for therapy.
Other future uses of human stem cells include exploration of the effects of chromosomal
abnormalities in early development and repair of the damaging side effects of medical
treatments. The former might include the ability to monitor the development of early
childhood tumors, many of which are embryonic in origin, while the latter could serve as
an approach to restore the immune cells in cancer patients who receive chemotherapy
treatments.
3.3 Technical Challenges
Before stem cells can be applied to human medical problems, substantial advances in
basic cell biology and clinical technique are required and formidable obstacles need to be
overcome. The most prominent technical hurdles in stem cell research include
developing the capacity to control the differentiation of stem cells into desired cell type
and ensuring that uncontrolled development, such as cancerous tumors, does not occur.
If stem cells are to be used for transplantation, the problem of immune rejection must also
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be overcome.
Until now, it has not been proved that specialized cells derived from cultured embryonic
stem cells can actually function within tissues after transplantation (Lumelsky et al 2001).
It may not be surprising as well that cells generated in vitro might not be equivalent to
those arising in vivo, given the extensive cellular interactions and "education" that take
place during development. Moreover, since most of our knowledge comes from
experiments in mice, scientists are not so sure so far that human stem cells possess the
same potential. Additionally, although human embryonic stem cells appear capable of
unlimited proliferation in vitro, it is still a matter of debate whether prolonged culturing
affects their pluripotency.
Studies also show that several established embryonic stem cell lines form teratomas,
benign tumors containing a mixture of tissue types, after being transplanted (Martin, G R.
1981). Therefore, ES cells must be reliably differentiated into the appropriate cell type
in culture before transplantation. In addition, most of the human embryonic stem cell
lines that have been isolated to date have been grown on beds of mouse "feeder" cells.2
Infectious agents, such as viruses, within the mouse feeder cells could transfer into the
human cells. If the human cells were transplanted into a patient, these infected human
cells may cause disease in the patient which could be transmitted to close contacts of the
patient and eventually to the general population. Therefore, to demonstrate the safety of
embryonic stem cells, researchers need to rule out any chance that the administration of
embryonic stem cells could cause tumor formation or the transmitting of infectious
agents.
2 In February 2001, Geron Corporation researchers presented findings at a scientific meeting demonstrating
that human embryonic stem cells can be maintained without mouse feeder cells. From NIH report Stem
cells: scientific progress and future research directions, June 2001. p. 95-96.
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Human embryonic stem cells can be obtained only from very early embryos and,
although several human ES-cell lines have been made, they will not be immunologically
compatible with most patients who require cell transplants. Unless the cultured cells are
placed in an immunoprivileged tissue, the use of immunosuppression may be required to
prevent immunorejection in humans during stem cell transplantation. For
immunoprivileged tissues like brain, researchers will need either to derive many more
embryonic stem cell lines or to genetically engineer embryonic stem cells on a
patient-by-patient basis to be tolerated by the host tissues.
Although those opposed to using human embryonic stem cells tout the possibility of
pluripotent adult stem cells as a way of realizing medical gain without ethical pain, stem
cells collected from tissues of adults or older embryos are typically more restricted in
their developmental potential. Recent studies have raised the possibility that some adult
stem cells can give rise to cells outside their tissue of origin (Jiang et al 2002). However,
these results are controversial and have often proved difficult to reproduce (Morshead et
al 2002). Another big hurdle to the clinical application of adult stem cell research is the
small number of cells that can be isolated from any adult tissue. Despite the recent
successful optimization of the proliferation ability of adult stem cells, it is still possible
that extensive culture of cells in vitro may subtly alter their intrinsic properties, rendering
them unfit for restoring injured or diseased tissues in patients. These technical barriers
help boost the voice of supporters of embryonic stem cell research and reinforce their
resolution to advocate for more ES-cell-friendly public policies and research
environment.
3.4 Scientific Timeline
Despite the challenging technical barriers it is facing today, stem cell research has never
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stagnated in bringing excitement to the scientific community ever since the dawn of the
stem cell age, with blockbuster discoveries one after another. A timeline is presented
below to illustrate the history of scientific progress in stem cell research. The recent
rapid technological advancement captured by the timeline also explains, to a large extent,
the flourish of stem cell firms in the last decade.
* In 1878, first attempts to fertilize a mammal's eggs outside the body were
reported (Trounson et al 2000).
* In 1959, first successful in vitro fertilization of animals (rabbits) in United States
was reported (Trounson et al 2000).
* In 1968, Edwards and Bavister fertilize the first human egg in vitro (Trounson et
al 2000).
* During 1970's, chimeric mice were produced by injecting embryonic stem cells
into mouse blastocysts and cultured embryonic stem cells are explored as models
of embryonic development (Martin 1980).
* In 1978, Louise Brown, the first IVF baby, is born in Oldham, England
(Trounson et al 2000).
* In 1981, Evans and Kaufman (1981), and Martin (1981) derived mouse
embryonic stem cells from the inner cell mass of blastocysts. They established
culture conditions for growing pluripotent mouse embryonic stem cells in vitro.
Also, the first in vitro fertilized baby in the United States, Elizabeth Carr, was
born in Norfolk, VA in the same year (Trounson et al 2000).
* In 1984, Andrews et al. developed pluripotent, genetically identical (clonal) cells
called embryonal carcinoma (EC) cells from Tera-2, a cell line of human
testicular teratocarcinoma (Andrews et al 1984).
* In 1989, Pera et al. derived a clonal line of human embryonal carcinoma cells,
which yields tissues from all three primary germ layers (Pera et al 1989).
36
* In 1993, Interneuron Pharmaceuticals Inc. discovered and characterized a stem
cell in mice that is believed to be the earliest lineage of cells for blood and
immune systems (The Wall Street Journal, March 30, 1993). Later in the same
year, deficient white blood cells were extracted from children (umbilical cord)
with immune-system disease, genetically made correct and then returned to the
boy in repeated infusion (The Wall Street Journal, May 17, 1993).
* In 1994, the inner mass cells extracted from human blastocysts created for
reproductive purposes using IVF and donated by patients for research were
maintained in culture and generated aggregates with trophoblast-like cells at the
periphery and ES-like cells in the center (Bongso et al 1994).
* In 1995, the first embryonic stem cells from non-human primates are reported
(Thomson et al 1995). The work by Wisconsin scientists, James Thomson, John
Hearn, et al., in rhesus macaques showed that it was possible to derive embryonic
stem cells from primates, holding out the possibility they might one day be
derived from humans.
* In 1996, Mouse embryonic stem cells were induced to begin differentiating down
a path toward heart muscle (Klug et al 1996).
* In 1998, Wisconsin biologist Dr. James A. Thomson and colleagues derived
human embryonic stem cells from the inner cell mass of normal human
blastocysts (Thomson et al 1998). The stem cells show the potential to develop
into nearly all of the body's tissue types. At the same time, Dr. John Gearhart
and colleagues reported that embryonic germ cells, derived from fetal tissue,
could also develop into the body's different tissue types (Shamblott et al 1998).
* In 2000, researchers discovered that skin stem cells, which prompt skin
regeneration, reside in hair follicles (Jahoda 2000). In the same year, Scientists
in Singapore and Australia led by Pera, Trounson, and Bongso derived human ES
cells from the inner cell mass of blastocysts donated by couples undergoing
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treatment for infertility. The ES cells proliferated for extended periods in vitro,
maintained normal karyotypes, differentiated spontaneously into somatic cell
lineages derived from all three primary germ layers, and formed teratomas when
injected into immune-deficient mice.
· In April 2001, Anthrogenesis Corp. announced that it had derived a new source
of stem cells from human placenta that may help researchers avoid ethical
problems associated with cells derived from human embryos or aborted fetuses
(The Wall Street Journal, Apr. 12, 2001). In the July of the same year, in a
demonstration that human embryonic stem cells may treat intractable disease, a
team of researchers of Johns Hopkins University led by John D. Gearhart and
Douglas Kerr restored motion to paralyzed rats by implanting the cells into their
spinal cords (The Wall Street Journal, July 25, 2001). In October, Geron
Corporation successfully grew human embryonic stem cells without using a layer
of mouse cells, potentially eliminating an obstacle to the commercialization of
stem-cell-based treatments (The Wall Street Journal, Aug. 28, 2001). In
November, Advanced Cell Technology, a biotech company in Worcester, MA,
announced that they had produced an embryo with human DNA which had
grown to the six-cell level. However, the technology will be used only to
generate stem cells for research. And in December, two separated researches
led by Su-Chun Zhang, a neurobiologist at the University of Wisconsin, and
Benjamin Reubinoff of the Hadassah University Hospital in Jerusalem,
successfully used human stem cells to generate new brain tissue in mice, an
advance that points the way toward potential treatments for diseases like
Alzheimer's and Parkinson's (The Wall Street Journal, Dec. 3, 2001).
· In June 2002, Advanced Cell Technology Inc. used skin cells from a steer to
make cloned embryos, which were then gestated inside surrogate cows for one to
two months. The cloned fetuses were harvested and then their heart, muscle and
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kidney tissues were transplanted back into the original steer. No organ rejection
response was found (The Wall Street Journal, June 3, 2002). And later in the
same year, Researchers from the Maxine Dunitz Neurosurgical Institute of
Cedars-Sinai Medical Center said they had found a way to use stem cells to
search out and destroy deadly tumor in the brains of mice (The Wall Street
Journal, Oct. 15, 2002).
* In 2003, scientists in James Thomson's lab report methods for recombining
segments of DNA within stem cells. The technique, known as homologous
recombination, gives researchers the ability to manipulate DNA in stem cells in
order to study gene function (Zwaka et al 2003).
* In February 2004, South Korean scientists report that they have created human
embryos through cloning and extracted embryonic stem cells (The Wall Street
Journal, Feb. 12, 2004).
3.5 Ethical Controversies
In spite of all the promising potentials human embryonic stem cells have demonstrated in
applications like regenerative medicines and cell-based therapies, however, the
development of a robust research community focused on embryonic stem cell
investigation, especially in the US, has been slowed by public policies that are derived
directly or indirectly from ethical, moral and religious considerations. The ethical
debate surrounding stem cell research has been primarily focusing on the source of the
human embryonic stem cells in that the derivation of such cells deprives a human embryo
of any further potential to develop into a complete human being. On August 9, 2001,
the U.S. President George Bush announced that the government would finance research
on 60 existing stem cell lines derived from excess embryos created solely for
reproductive purposes, where the life and death decision has already been made, but not
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new ones. For those who hold the view that the embryo is a human life from the
moment of fertilization, the derivation of stem cells from either very early or
pre-implantation embryos created by in vitro fertilization or from the tissues of aborted
fetuses is ethically unacceptable. From this point of view, even though the Bush
Administration does not support activities which directly destroy embryos, its support of
research on components of the embryo is deeply disturbing.
Supporters of this view argue that the possible benefits of stem cell research cannot and
should not justify the action necessary to obtain the cells. Augments in favor of
imposing constraints or even an outright prohibition on embryonic stem cell research are
frequently supported by the assertion that research on stem cells from adult tissues alone
could provide similar therapeutic benefits without the need for embryonic or fetal cells.
However, much of the evidence supporting such arguments is suggestive rather than
definitive and the hurdles so far encountered in research on adult stem cells suggest that
prediction of success are highly speculative. Therefore, many scientists do not agree
that adult stem cells hold as much potential as embryonic stem cells.
Supporters of embryonic stem cell research believe that pre-implantation embryos do not
raise the same legal and moral issues as human beings in that they lack specific capacities,
including consciousness, reasoning and sentience (Steinbock 1994). Advocators also
argue that the potential human health and scientific benefits the embryonic stem cell
research holds should be an ethical argument for its support as well. Patient groups
have asserted that, because of the clinical potential human stem cells hold for disease
treatment, it is immoral to discourage or even stifle such research. Additionally,
supporters believe that the oversight that would come with federal grant support would
result in better and more ethically controlled research than if funding was solely from
private sources.
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Although the Bush Administration August 9 policy decision on stem cell research well
balanced between the President's commitment to preserving the value and sanctity of
human life and his desire to promote vital medical research, it placed some fundamental
barriers to stem cell research as well. For example, it is known to the stem cell
scientists that the small the number of cell lines in use, the lower the genetic diversity that
they present. The prohibition on the derivation of new cell lines could result in research
that focuses on cell lines that are not optimal and might preclude the replacement of
inferior materials with more efficient cell lines. It has also been suggested that it is
biologically preferable to derive stem cells from embryos created specifically for research
rather than from surplus embryos at in vitro fertilization clinics. This is because couples
who have turned to treatment for infertility might have inherent, but as yet unrecognized,
biological defects.
3.6 Stem Cell Regulation and Legislation Timeline
Due to the ethical, moral and religious challenges human embryonic stem cell research
has incurred, it becomes a source of major political controversy in the United States. A
timeline regarding the stem cell related American policies will provide some useful
information on how the country balances the scientific promise and its consequent
economic gains, and the ethical dilemma in stem cell research. In the meantime, the
strong government intervention illustrated by the timeline tells us in a sense how
important political networking could be to a stem cell company.
In 1996, the Dickey Amendment (Public Law 106-554, Sec. 510) which was
originally sponsored by Rep. Jay Dickey (R-Ark.) was enacted, prohibiting
Department of Health and Human Services from using appropriated funds for the
creation of human embryos for research purposes or for research in which
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embryos are destroyed.3
* In November 1998, following the announcement by the University of Wisconsin
and Johns Hopkins University on the derivation of human embryonic stem cells,
President Clinton asked National Bioethics Advisory Committee (NBAC) to
conduct a review of the issues associated with stem cell research, which NBAC
released in January 2001 and was entitled "Ethical Issues in Human Stem Cell
Research.4
* In January 1999, Department of Health and Human Services determined that the
ban on federal funding of human embryo research did not prohibit funding
human embryonic stem cell research. It then announced that it could legally
fund research on embryonic stem cells, the primitive cells present in embryos and
fetuses, but NIH would not finance any studies until it developed guidelines for
the controversial research and convened a special committee to review all such
proposals (The Wall Street Journal, Jan. 20, 1999).
* In August 2000, National Institutes of Health issued final guidelines for funding
stem cell research and began accepting grant application for research projects
utilizing human stem cells immediately following publication of the guidelines.
All applications were to be reviewed by the NIH Human Pluripotent Stem Cell
Review Group (HPSCRG), which was established to ensure compliance with the
guidelines. Applications would have also undergone the normal NIH peer-review
process.
· In April 2001, the Bush Administration postponed the first meeting of the
HPSCRG and put federal funding for stem cell research projects on hold, pending
a review of Clinton Administration policy decisions on stem cell research
(Bohene 2001). In the same month, Stem Cell Research Act of 2001, originally
sponsored by Sen. Specter, was introduced to give NIH authority to fund the
3 Source: Thomas Legislative Information on the Internet: http://thomas.loc.gov/.
4 The NBAC report is available at http://biocthics.gcogctown.cdunlbac.
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derivation of stem cells from surplus IVF embryos, an activity prohibited by the
Dickey Amendment. In contrast, the bill broadly prohibited support of embryo
research unrelated to stem cells.
· In June 2001, the Responsible Stem Cell Research Act was introduced to
authorize the Secretary of HHS to establish a National Stem Cell Donor Bank in
order to make "qualifying human stem cells" available for research and
therapeutic purposes. Qualifying human stem cells are defined in the bill as
"human stem cells obtained from human placentas, umbilical cord blood, organs
or tissues of a living or deceased human being who has been born, or organs or
tissues of unborn human offspring who died of natural cases, such as spontaneous
abortion.
* In July 2001, Sen. Bill Frist (R-Tennessee), a Bush ally, joins anti-abortion
Senator Orrin Hatch (R-Utah) in backing limited funding for stem cell research.
Later in the same month, House Speaker Dennis Hastert (R-Illinois) joins other
GOP House leaders in opposing funding for research.5
* On August 2, 2001, Rep. DeGette introduced Stem Cell Research for Patient
Benefit Act, which would require NIH to support research on human embryonic
stem cells derived from embryos or fetal tissue in accordance with the NIH
guidelines published in August 2000.
* On August 9, 2001, President Bush announced that federal funds would only be
used for research on existing stem cell lines that were derived: (1) with the
informed consent of the donors; (2) from excess embryos created solely for
reproductive purposes; and (3) without any financial inducements to the donors.
And later in that month, NIH named the developers of 64 embryonic-stem-cell
lines eligible for study using government funds (The Wall Street Journal, Aug. 28,
2001).
5 The Heartland Institute - Timeline: Stem Cell Research Debate:
http://'www.hcaltland.org/Articlc. cfim?artId=554.
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* In September 2001, Rep. Millender-McDonald introduced New Century Health
Advantage Act, which would repeal the prohibition on using federal funds for
embryo research and direct the NIH to conduct or support research on human
stem cells that were derive from embryos that were created for fertility treatments
and were in excess of clinical need.
* On September 11, 2001, the National Academies released a report entitled Stem
Cells and the Future of Regenerative Medicine. The report recommends that
research on both adult and human embryonic stem be pursued.
* In November 2001, NIH unveiled its registry of embryonic stem cells eligible for
federal funding. (The Wall Street Journal, Nov. 8, 2001) As shown in Table 2,
this Human Embryonic Stem Cell Registry listed 14 universities and companies
that had derived a total of 78 human embryonic stem cell lines which were
eligible for use in federally funded research under the August 2001 Bush
Administration policy. However, eventually many of these stem cell lines were
found to be either unavailable or unsuitable for research.
* In April 2002, Rep. Maloney introduced the Science of Stem Cell Research Act,
which would establish for four years the Stem Cell Research Board, a bipartisan
legislative branch commission. The Board would be required to research (1) the
effects of the President's August 9, 2001, stem cell research directive, including
progress in advancing disease cures and improving organ transplantation; and (2)
the effect of limiting Federal funding on the private stem cell research sector and
the funding process of the NIH for human adult and embryonic stem cell research.
Later in the same month, The Department of Health and Human Services
announced a $3.5m grants to be paid out over two years to BresaGen Inc., ES
Cell International, University of California, San Francisco and Wisconsin Alumni
Research Foundation (The Wall Street Journal, Apr. 29, 2002).
* In February 2003, Sen. Hatch introduced Human Cloning Ban and Stem Cell
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Research Protection Act to prohibit human cloning and protect stem cell
research.
* In June 2003, Rep. Smith introduced Cord Blood Stem Cell Act which amended
the Public Health Service Act to establish a National Cord Blood Stem Cell Bank
Network to prepare, store, and distribute human umbilical cord blood stem cells
for the treatment of patients and to support peer-reviewed research using such
cells. In October 2003, Sen. Hatch introduced the same amendment in Senator.
* In March 2004, Harvard University scientists used private funds to create 17 new
populations of embryonic stem cells that would be available immediately to
scientists around the world (The Wall Street Journal, Mar. 4, 2004). Later in the
same month, Rep. Millender-McDonald introduced Stem Cell Replenishment Act
to authorize the use of Federal funds for research on human embryonic stem cells
irrespective of the date on which such stem cells were derived.
Table 2: Original NIH List of Stem Cell Lines Eligible for Use in Federal Research
XiIN~umero
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BresaGen, Inc., Athens, GA 4
CyThera, Inc., San Diego, CA 9
ES Cell International, Melbourne, Australia 6
Geron Corporation, Menlo Park, California 7
Goteborg University, Goteborg,, Sweden 19
Karoliska Institute, Stockholm, Sweden 6
Maria Biotech Co. Ltd. - Maria Infertility Hospital Medical
Institute, Seoul, Korea
MizMedi Hospital - Seoul National University, Seoul, Korea 1
National Center for Biological Sciences/Tata Institute of
Fundamental Research, Bangalore, India
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Pochon CHA University, Seoul, Korea 2
Reliance Life Sciences, Mumbai, India 7
Technion University, Haifa, Israel 4
University of California, San Francisco, CA 2
Wisconsin Alumni Research Foundation, Madison, WI 5
Note: Universities and companies in grey are no longer listed in the NIH Registry.
Currently there are only nine stem cell lines are available from four sources: BresaGen,
Inc. (one stem cell line); ES Cell International (five stem cell lines); University of
California at San Francisco (one stem cell line); and Wisconsin Alumni Research
Foundation (two stem cell lines).
3.7 Stem Cell Industry - Commercial World Brief
Although the human hematopoietic stem cells have long been used clinically through
bone marrow transplantations to save patients with diseases like leukemia, the stem cell
industry did not reach its heyday until the breakthroughs from Thomson's and Gearhart's
labs in 1998, when embryonic stem cells were first isolated. Even though it has been
more than 6 years since the stem cell research and the accompanying technologies
virtually started exploding, such research is still in its infancy stage, and many of the
enabling and complementary technologies impacting stem cells are only now catching up
to the rate of research. For example, without the nearer-term prospect of
xenotransplantation products, it would have been impossible to launch a company
exclusively on stem cells.
There weren't a lot of academic or government grants going into the stem cell area at the
start. John Gearhart's work in first successfully extracting embryonic germ cells from
human fetal tissue and proving that they could develop into the body's different tissue
types was financially backed by Geron, a small private biotech company at the time.
Although Gearhart approached the National Institute of Health first for funding his efforts
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to derive stem cells from aborted human fetuses, which both legal and within NIH's
guidelines, he received brush-off as the proposed work was too hot to handle.
However, private money was relatively easy to come by when the stem cell industry
initially took off. Investors weren't hesitant about pouring cash from the booming stock
market into biotech firms, which were also riding a wave of excitement generated by the
race to sequence the human genome besides the promising potentials discovered in
human pluripotent stem cells. Share prices of many stem cell firm stocks hit their peaks
in early 2000. Such stem cell firms included Geron and PPL Therapeutics, which was
mainly in animal cloning but also ran stem cell projects.
Unfortunately, stem cell researchers haven't been likely to receive that kind of private
manna since then. The stock market slump made the venture capital almost nonexistent.
According to the biotech analysts BioCentury, the amount of venture capital invested in
cell therapy companies has fallen 50% in 3 years, to $50.2 million in 2002, mirroring the
plunge in stock prices in the sector. One of the hottest areas of all - human embryonic
stem cells and therapeutic cloning, the creation of stem cell lines that are identical
genetically to a prospective patient's - was hit particularly badly.
Big pharmaceutical companies have been of no big help as well. The idea that broken
body parts could be replaced with fresh healthy cells is appealing, but most major drug
and biotech companies have been reluctant to develop any kind of cell therapy. This is
because treatments are likely to be far more difficult to develop than even the most
complex drugs. They could also be prohibitively expensive. The precedents of many
failed stem cell firms also kept the pharmaceutical giants from even dipping their toes
into the field of stem cell research. Old-school drug companies like Pfizer and Merck
prefer simple medicines made from small molecules - the opposite of a cellular therapy.
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For the drug industry's smart money, stem cells have been one bet too risky to make,
given the long development cycle for stem cell products and the associated costs
involved.
Money, along with brains, is draining from the field, despite President Bush's vow in
August 2001 to commit federal funds to research human embryonic stem cells.
Advanced Cell Technology, a private held firm in Worcester, MA, has lost three of the
four high-profile scientists it recruited in early 2001. Publicly traded companies aren't
doing much better. For instance, Geron laid off almost half of its work force in 2003,
including two dozen who were involved primarily in stem cell research, and cut research
spending to bolster its lagging stock price.
Besides the downside of the stock market, the ethical controversy of the stem cell
research has kept would-be investors on the sidelines as well. In such a predicament,
the vast majority of stem cell scientists in the United States will have to rely for funding
from public sources like federal government. However, although the Bush
Administration did allow stem cell research projects to receive governmental grants, it
restricted all federally funded work on embryonic stem cells to cell lines derived before
August 9, 2001, but not any new ones. This seriously reduced the genetic diversity
presented by stem cells in federally funded research. And the access to the approved
lines is often slow. Moreover, of the 78 stem cell lines worldwide the Bush
administration has said are eligible for federally funded research, only about a dozen are
in good enough shape to experiment on. Even fewer - so far only nine cell lines from
four suppliers (see Table 2) - are being shared and sent to other researchers interested in
breaking into a field already clouded with political, ethical and scientific questions. For
instance, the seven NIH-approved cell lines in India cannot be shipped because of that
country's laws. Geron would not ship any of its lines unless researchers agree to sign
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over any discoveries to the company.
Despite all the difficulties in the efforts to commercialize the stem cell research, it still
holds growth potential. Some foreign countries, such as Australia and Switzerland, are
regarded as islands of stability in the uncertain stem cell world. ES Cell International, a
company based in Australia and Singapore who owns five of the NIH-approved stem cell
lines, added staff in 2003 while other stem cell firms downsized. In December 2002, it
even bought the rights to diabetes-related stem cell research at Curis, a biotech firm based
in Boston, whose staff members remains in Boston but work for ES Cell International.
Such external partnering was mentioned in the work of Greis et al. (1995) as a response
to innovation barriers in the biotechnology area today. At least in a short period of time
into the future, this kind of arrangement may become more prevalent.
Another recent trend may be more encouraging to United States based stem cell firms.
Some deep-pocketed drug makers are changing their attitude towards the stem cell
research and testing the water of this field. In late December 2003, Amgen, the world's
largest biotechnology company, invested $20 million in Boston's ViaCell, a 260-person
privately held company specializing in umbilical cord stem cells. ViaCell's proprietary
technology that creates a supply of stem cells large and pure enough to be used as a
therapy really set it apart as none of other technologies that attempted to grow cord blood
cells outside the body have ever worked. In addition, because stem cells derived from
umbilical cords are less versatile than embryonic stem cells, while embryonic stem cells
still face big manufacturing and regulatory hurdles, and have yet to be tested in humans,
ViaCell's umbilical cord product is entering human trials. The prospect of being close to
some substantial outcomes also helped the firm secured Cambridge, MA.-based Genzyme,
the third-biggest biotech, as another major investor.
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Amgen's deal with ViaCell, which could be a harbinger of more to come, also implies
that to receive more research sponsorship, stem cell companies will have to spin their
results so that shareholders can see the excitement. After all, it is no longer the same
level of excitement about stem cell industry as people saw a few years ago.
To sum up, in spite of all the excitement stem cell research has been generating, stem cell
companies are experiencing severe financial hardship in the United States today. In an
industry of early development stage where basic research is imperative, government
grants should be the best source of funding. However, in the case of stem cell field,
stringent public policies make it almost impossible for abundant public funding to flow
into the industry. The stagnancy of the stock market and the depression of the overall
social economy lead to a disappointing drought of private investment in stem cell
research as well, while migration overseas to countries with more stem cell friendly
policies and strategic alliance with big biotech companies can only partially solve the
puzzle. All of the above lays a perfect ground for the inner circle, which uses its
leverages across the scientific, commercial and regulatory domains to strive for welfare
of a wide range of stem cell firms, to breed and thrive.
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CHAPTER 4: METHODOLOGY
4.1 Sampling
There are more than 90 companies involved in the development of cell based therapies in
the United States. The list of the companies is presented in Appendix 2. Only a small
fraction of these firms are involved in stem cell technologies directly, either providing
sources for stem cells or developing technologies for stem cell transplantation. Other
companies provide technologies for cell culture, cell lines and cell sorting, or provide
encapsulation technologies for cell transplantation. There are also a few gene-therapy
companies with technologies for ex-vivo genetic modification of cells and some vaccine
companies which are developing cell-based cancer therapy. In addition, a number of
tissue engineering companies and companies involved in regenerative medicine are also
developing cell therapies. Finally, some companies are providing supportive services
for testing and regulatory approval of cell-therapy products. In this thesis, firms with
direct stem cell technologies involvement are the primary concern.
A sample of 12 stem cell companies6, as listed in Table 3, is carefully selected for the
study of inner circle in the American stem cell industry. Not only are all of them
actively pursuing stem cell technologies directly, but a significant part of their research
effort is devoted to the neural stem cells, which have been deemed as the key to curing
such afflictions as spinal cord injury, Parkinson's and Alzheimer's in the future.
Table 3: Name, Location and Type of Funding Sources of the Sample Stem Cell Finns
6 One of the sample firms, StemCells Inc, used to be a small stem cell company based in San Diego, CA
and was acquired by Cytotherapeutics Inc, a Providence, RI -based stem cell firm in 1997. In August
2000, Cytotherapeutics Inc changed its name back to StemCell Inc. In this thesis, the data of
Cytotherapeutics Inc, which is taken into account as the preexistence of StemCell Inc, are collected and
used too.
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'',-."..:"' "._' '" . .,. -,':... A .n -NameJ Locatio  S.r..
Advanced CellWorcester, MA Private Neurodegen/DiabetesWorcester, MA PrivateTechnology
Boston Life Sciences Boston, MA Public CNS* and Cancer
Parkinsons/Spinal
Diacrin Charleston, MA Publicnsons/SpinalCord/Liver/Cardiac
Geron Corporation Menlo Park, CA Public CNS/Cardiac/Diabetes
Layton BioSciences Sunnyvale, CA Private CNS
NeuralStem
Biopharmaceuticals Gaithersburg, MD Private CNSBiopharmaceuticals
Neuronyx Malvern, PA Private SpinalCord/Brain/Parkinsons
ProNeuron Spinal Cord/Multiple
Biotechnologies Los Angeles, CA Public Sclerosis/Glaucoma/Biotechnologies Parkinson's/Alzheimer's
Saneron CCEL Temple Terrace, Private Parkinson's/Alzheimer's
Therapeutics FL
StemCells Inc
(formerly Palo Alto, CA Public CNS/Liver/Diabetes
CytoTherapeutics)
Titan CNS/Cancer/
.ita San Francisco, CA PublicPharmaceuticals Cardiovascular Disease
Expansion of HSCs forViacell Boston, MA Privatension of HSCs for
Neurology & Diabetes
*Central Nerve System
**Human Stem Cells
In addition, the commercial activities of the sample firms, represented by their patent
filing behaviors, seamlessly tally with the ups and downs of the American stem cell
industry. The number of patents filed by the sample stem cell firms7, which is
illustrated in Table 4, perfectly embodies the steep commercial takeoff of the American
stem cell industry in 1998. Before that, the total number of patents filed by sample stem
cell firms was gradually increasing since the first sample firm Cytotherapeutics, Inc., the
preexistence of StemCell, Inc. was established. The number proliferated in 1998,
7 The assignees of the patents are the sample stem cell firms.
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matching the huge scientific discoveries taking place that year and the consequent
industrial hype in stem cell commercialization in the year to follow.
Table 4: Patent Years and Number of Patents of the Sample Stem Cell Firms
iPatent· .Numbers of a um
Y! ea :: P Ptenting Firms : (Number; f Patentlsi:; - q>!¢ '; ''
1993 2 Pro-Neuron (2)
1995 2 Pro-Neuron (2)
1996 24 Cytotherapeutics (9), Diacrin (3), Geron (10) and
1995 24 Pro-Neuron (2)
1997 45 Cytotherapeutics (29), Diacrin (4), Geron (9) and
Pro-Neuron (3)
1998 139 Cytotherapeutics (84), Diacrin (1), Geron (50) and
Pro-Neuron (4)
1999 83 Cytotherapeutics (32), Diacrin (2), Geron (42) andPro-Neuron (5)
2000 37 Cytotherapeutics (3), Diacrin (2), Geron (12), Layton
(1), NeuralStem (1) and Pro-Neuron (18)
Diacrin (8), Geron (28), NeuralStem (2), Pro-Neuron
(22), StemCells (1) and Titan (2)
Boston Life Sciences (4), Cytotherapeutics (2),
2002 55 Diacrin (5), Geron (28), Pro-Neuron (11), StemCells
(3) and Viacell (2)
Boston Life Sciences (4), Diacrin (6), Geron (67) and
Titan (2)
Source: United States Patent and Trademark Office
Moreover, the number of patents filed by the sample companies also captured the recent
moderate turnaround of the American stem cell industry in terms of the
commercialization activities. Having experienced the downside of stock market and
decreased excitement about the stem cell research incurred by growing ethical pressure
and political constraints during years 2001 and 2002, the stem cell industry has been
gaining momentum again through cross-nation cooperation and with financial input from
the big bio-pharmaceutical companies since 2003, as revealed vividly in Figure 1.
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Figure 1: Average Number of Patents Invented by the Sample Stem Cell Firms
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4.2 Definitions
How this thesis searches for the stem cell inner circle is visualized in Figure 2. First of
all, the boundaries of the scientific, commercial and governmental domains in the stem
cell field are defined. A pool of objects - people who satisfy those definitions - is then
sought out for each of the domains from a greater pool of people who are generally
engaged in the cause of stem cell technology. Finally, by overlapping the three pools,
people who are situated in the intersection of the three domains can be identified as the
members of this stem cell inner circle.
Figure 2: Inner Circle in the Stem Cell Industry - the Overlap of Scientific, Commercial
and Governmental Activities
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Since the stem cell inner circle people are defined as being most active across all three
types of activities that stem cell firms participate in, they should first be star scientists in
terms of stem cell research. As the thesis title indicates, the stem cell inner circle is in
fact a web of science - a web of power originated in the stem cell scientific community.
While it is almost impossible to capture all the scientists who are doing research on stem
cells, a boundary that is broad enough to include most of them has to be drawn. In this
thesis, a list of scientists who are cited or interviewed in either the NIH Stem Cell Report
(2001) or NAS Stem Cell Report (National Research Council 2001) and scientists who
have ever published stem cell papers in the Tissue Engineering journal is believed to
serve well as a broad yet attainable boundary for stem cell scientists. Among those
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scientists, only the most prominent ones are eligible to form the Scientific circle in Figure
2. A scientist is normally perceived to be more authoritative in her research area if her
work is more highly cited. Therefore, frequency of citation is considered an indicator of
the prominence of a scientist in this study. Stem cell people who are playing active roles
in the scientific domain are finally defined as scientists whose names appear in NIH Stem
Cell Report, NAS Stem Cell Report or stem cell related papers in Tissue Engineering
with high citation frequencies.
Coauthorship was concluded in the work done by Zucker et al. (2001) as a robust
indicator of a firm's tacit knowledge capture and strong predictor of its success.
Therefore, a complete co-publishing list is collected for each of the 12 sample stem cell
firms as a partial measure of commercial activities. Since being founders and Scientific
Advisory Board members is regarded as primary commercial activities, a thorough list of
founders and SAB members is obtained for each of the sample firms as well. In
addition, an exhaustive list of patents whose assignees were one or more of the sample
firms and which were filed during the decade of 1993 - 2003 is collected.
The active participants of the stem cell related commercial activities are defined as the
intersection of the three set of data described above. Therefore, the qualified stem cell
commercial activists need to satisfy all of the following three criteria:
* Founders or SAB members of one or more stem cell firms
* Having papers co-published with one or more stem cell firms
* Having patents filed with one or more stem cell firms
Besides being star scientists and commercial activists, members of the stem cell inner
circle should have close governmental association too. In this thesis, such governmental
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involvement is defined to include appearance at Congressional and Senator Hearings
about research on stem cell and human embryos, and the appointment or membership in
various NIH National Advisory Councils and NIH Stem Cell Taskforce and Working
Groups. Those governmental activities well represent inner circle members' advisory
functions to stem cell related regulatory and legislative agencies on the federal level.
Finally, overlapping the pools of the people who compose the three circles in Figure 4
generates a core group of people who are most active participants in the stem cell related
scientific, commercial and governmental activities. As illustrated as the question mark
area in Figure 4, this intersection represents the power elite of the stem cell industry - the
stem cell inner circle, which is the ultimate pursuit of this thesis.
4.3 Data Sources
Doing power structure research often entails tracking down biographical information on
individual political and economic elites. Until recently, most of the information needed
to trace the webs of power in American society could be obtained only through extensive
library and archival research, close monitoring of the press, searches of government
records and documents, and interviews with knowledgeable insiders. These remain
important sources of data for power structure research, but today much of the information
previously obtained in these ways can now be acquired more quickly and easily on the
Internet from sources like proprietary databases.
As mentioned earlier, in search for the people eligible to fill in the Scientific circle, NIH
Stem Cell Report, NAS Stem Cell Report and Tissue Engineering are used to form a
boundary for general stem cell scientists. The ISIHighlyCited databases provides a list
8 ISIIIighlyCitcd database: http:',!isi6.isiknowlcdgc.corn/portal.cgi?DcstApp -I ICR&Func=Framrnc.
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of the highly cited scientists in such areas as Molecular Biology, Genetics, Biology,
Biochemistry, Immunology, Clinical Medicine and Neuroscience.
Among the data sets used to generate the Commercial circle, the co-publishing lists of the
sample firms are derived from ISI Web of Science9, a database containing information
gathered from thousands of scholarly journals in all areas of research. Each of the
co-publishing lists contains the information including author, ISSN number, title,
document type, cited references count, source abbreviation, source, keywords, times cited,
abstract, address, IDS number and total number of papers that each author has published
with the firm. The lists of founders and SAB members are obtained through phone
interviews and email contact with the targeted firms as well as Internet search on the firm
websites. Finally, the lists of patents are collected from the database of United States
Patent and Trademark Office. Each of the patent lists contains information including
patent number, patent date, inventors, inventor location, firm, firm location and applied
date.
In order to search for relevant information about regulatory and legislative activities in
the stem cell field, databases like Lexis-Nexis, Federal Advisory Committee Act (FACA)
databases, Thomas Legislation Information I, etc. are used to generate the lists of people
who appeared at any Congressional and Senator Hearings about research on stem cell and
human embryos. NIH appointment and membership information is obtained from the
rosters of various NIH National Advisory Councils and Stem Cell Taskforce and Working
Groups. NIH stem cell related National Advisory Councils includes:
* National Advisory Council on Aging
9 ISI Web of Science: http://isi6.isiknowledge.com/portal.cgi?DestApp=WOS&Func=Frame.
10 Federal Advisory Committee Act (FACA) database: http://www.fido.gov/facadatabase/.
!l Thomas Lcgislation Information: http://thomas.loc.ov/l.
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· National Heart, Lung, and Blood Advisory Council
* National Advisory Council for Complementary and Alternative Medicine
* National Advisory Council for Biomedical Imaging and Bioengineering
* National Advisory Child Health and Human Development Council
* National Diabetes and Digestive and Kidney Diseases Advisory Council
* National Neurological Disorders and Stroke Advisory Council
NIH Stem Cell Task Force and Working Groups include:
* NIH Stem Cell Task Force
* Stem Cell Research Career Pathways Working Group
* Stem Cell Research Resource Access Working Group
* Peer Review of Stem Cell Science Working Group
* Supporting Technologies/Research Tools in Basic Research Working Group
* Scientific Progress/Community Outreach Working Group
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CHAPTER 5: RESULTS
5.1 Results Delivery
By overlapping the pool of scientists whose names appear in NIH Stem Cell Report, NAS
Stem Cell Report or stem cell papers in Tissue Engineering and the pool of highly cited
scientists, a group of 46 star scientists - stem cell scientists who play critical roles in the
scientific world as early defined and illustrated as the Scientific Circle in Figure 2 - is
identified. The complete list of those scientists is included in Table 5.
Table 5: Names and Affiliations of the Scientists Whose Names Appear on NIH Stem
Cell Report, NAS Stem Cell Report or Stem Cell Related Papers in Tissue Engineering
and Who Are Also Highly Cited
Name Affidiation ·
Baltimore, David California Institute of Technology
Barker, Jeffery L. National Institute of Neurological Disorders and Stroke
Black, Ira B. University of Medicine & Dentistry of New Jersey
Bloom, Barry R. Harvard University
Bradley, Allan Baylor College of Medicine
Brinster, Ralph L. University of Pennsylvania
Choi, Dennis Wonkyu Washington University in St. Louis
Cohen, J. John University of Colorado Health Sciences Center
Crystal, Ronald G. Cornell University
Dzau, Victor J. Harvard Medical School
Fahn, Stanley Neurological Institute
Gage, Fred H. Salk Institute for Biological Studies
Habener, Joel Francis Massachusetts General Hospital
Hogan, Brigid L.M. Vanderbilt University School of Medicine
Hunder, Gene G. Mayo Clinic and Foundation
Hynes, Richard 0. Massachusetts Institute of Technology
Jaenisch, Rudolf Whitehead Institute
National Institute of Dental and Craniofacial Research,Kleinman, Hynda K. NIH
Kunkel, Louis M. Children's Hospital Boston
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National Institute of Environmental Health Sciences, NIH
Langston, J. William
Lee, Virginia Man-Yee
Martin, Gail R.
McKhann, Guy
McMahon, Andrew P.
Meister, Alton
Melton, Douglas A.
Mulligan, Richard
Charles
Phillips, Joseph H.
Rich, Alexander
Roberts, Robert
Rowley, Janet D.
Sanders, Jean E.
Shay, Jerry W.
Shimizu, Yoji
Steinberg, Daniel
Storb, Rainer
Struhl, Kevin
Thomas, E. Donnall
Trojanowski, John Q.
Verma, Inder M.
Vogelstein, Bert E.
Weissman, Irving L.
Wong, Gordon G.
Yamada, Kenneth M.
Yamamoto, Keith R.
Parkinson's Institute
University of Pennsylvania School of Medicine
University of California, San Francisco, School of
Medicine
Johns Hopkins University School of Medicine
Harvard University
Cornell University Medical College
Harvard University
Harvard Medical School
DNAX Research Institute of Molecular and Cellular
Biology
Massachusetts Institute of Technology
Baylor College of Medicine
University of Chicago
Fred Hutchinson Cancer Research Center
University of Texas Southwestern Medical Center at
Dallas
University of Minnesota Medical School
University of California, San Diego
Fred Hutchinson Cancer Research Center
Harvard Medical School
Fred Hutchinson Cancer Research Center
University of Pennsylvania School of Medicine
Salk Institute for Biological Studies
Johns Hopkins Oncology Center/HHMI
Stanford University School of Medicine
U.S. Genomics
National Institute of Dental and Craniofacial Research,
NIH
University of California, San Francisco
To identify the most active participants in the stem cell related commercial activities, the
co-publishing lists of the 12 sample companies are merged into one complete list. So
are the patent lists and the lists of founders and SAB members of the sample firms. The
intersection of the combined co-publishing list, patent list, and founder and SAB member
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Kunkel, Thomas A.
list represents the group of commercial activists who form the Scientific circle in Figure 2.
The list of this group of people is listed in Table 6.
Table 6: Information about People Who Are Playing Active Roles in
Related Commercial Activities
the Stem Cell
- ':.- - Number of. Numbe rof
~~~~~Fix ~~~~ --. Ad tenvits*: .P:
Advanced Cell Atala, Anthony SAB Member 27 1
Technology
Advanced Cell Campbell, Keith
Technology Henry Stockman SAB Member 3 1
Advanced Cell Golueke, Paul Founder 6 8
Technology
Advanced Cell Mombaerts, Peter SAB Member 1 2
Technology
Advanced Cell Robl, James Founder 7 11Technology ....
Advanced Cell
Technology
Boston Life Lanser, Marc Founder&SAB 3 6
Sciences
Cytotherapeutics Aebischer, Founder 15 14
Patrick
Cytotherapeutics Cooper, Stuart SAB Member 7 3
Diacrin Brown, Robert SAB Member 1 1
Diacrin Sachs, David SAB Member 12 1
Geron Corporation Campisi, Judith SAB Member 4 2
Geron Corporation Shay, Jerry SAB Member 22 16
Geron Corporation West, Michael Founder 21 9
Geron Corporation Wright, SAB Member 22 7
Woodring
LaytonLayton Eberwine, James Founder&SAB 11 1
BioSciences
Layton Lee, Virginia Founder 10 2
BioSciences
Layton Trojanowski, Founder 8 1
BioSciences John
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ProNeuron
Biotechnologies
ProNeuron
Biotechnologies
Saneron CCEL
Therapeutics
Saneron CCEL
Therapeutics
StemCells Inc
StemCells Inc
Viacell
Viacell
Cohen, Irun
Weiner, Howard
Sanberg, Paul
Saporta, Samuel
Gage, Fred
Weissman, Irving
Daley, George
Finklestein, Seth
SAB Member
SAB Member
Founder
SAB Member
SAB Member
Founder
SAB Member
Founder
29
30
20
2
21
19
1
4
2
1
9
5
4
7
1
3
*Number of patents whose assignees are one or more sample stem cell companies.
**Number of papers co-published by the scientists and one or more sample stem cell
companies.
While the data in the Scientific and Commercial circles can be statistically presented
above, the complete list of the people in the Governmental circle is too large to be
included in this thesis. This list consists of thousands of appointed officials and
advisors who have ever served on any of the stem cell related NIH National Advisory
Councils, Stem Cell Taskforce and Working Groups as well as people who have ever
appeared on Congressional and Senator Hearings regarding research using stem cells and
human embryos.
The overlap of the Scientific and Governmental circles is composed of people who are
not only prominent stem cell scientists but at the same time active participants in
federal-level regulatory and legislative activities regarding stem cells. 24 star scientists,
as listed in Table 7, are found to be serious national advisors to stem cell related policy
making.
Table 7: Names, Affiliations and Government Participations of Scientists Who Are in the
Overlap of Scientific and Governmental Circles
64
-- 
I^
Name Affiliation Governmental Association*
1996-Present National Institutes of
Baltimore, David California Institute of Technology Health AIDS Vaccine Research
Committee Chair
2000-Present Senior Investigator
National Institute of Neurological
Barker, Jeffery National Institute of Neurological
Disorders and Stroke, NIH,L. Disorders and Stroke
Laboratory of Neurophysiology,
Division of Intramural Research
1993-1994 Member, Search
Committee for Directorship of
National Institute of Neurological
Black, Ira B. Disorders and Stroke; 1992-1994Dentistry of New Jersey Chairman, Neuroscience
Subcommittee, Mental Health
Special Projects Review Committee
2003 Selected for the Hall of Honor
University of Pennsylvania by National Institute of Child Health
and Human Development
2000-Present National Institutes of
Choi, Dennis Washington University in St. Health Member/Director's Panel to
Wonkyu Louis Review the NINDS Intramural
Program
1991-1994 National Institute on
University of Colorado Health Allergy and Infectious Diseases,
Cohen, J. John Sciences Center NIH, Immunology Training Grant
Principal Investigator
1996-1998 National Institutes of
Crystal, Ronald Health, National Gene VectorCornell University
G. Laboratory Member, Scientific
Review Board
1999-2004 National Institutes of
Health, Morris K. Udall Center ofFahn, Stanley Neurological Institute orExcellence for Parkinson's Disease
Research Director
1999 NIH Member/Working
Group/Guidelines for Use of Human
Gage, Fred H. Sak Institute for BES Cells; 1998-2001 NIH
Member/National Advisory Council
on Aging
65
Habener, Joel
Francis
Hynes, Richard
0.
Kleinman,
Hynda K.
Kunkel, Thomas
A.
Lee, Virginia
Man-Yee
McKhann, Guy
Melton, Douglas
A.
Roberts, Robert
Sanders, Jean E.
Shay, Jerry W.
Shimizu, Yoji
Struhl, Kevin
Trojanowski,
John Q.
Massachusetts General Hospital
Massachusetts Institute of
Technology
National Institute of Dental and
Craniofacial Research, NIH
National Institute of
Environmental Health Sciences,
NIH
University of Pennsylvania School
of Medicine
Johns Hopkins University School
of Medicine
Harvard University
Baylor College of Medicine
Fred Hutchinson Cancer Research
Center
University of Texas Southwestern
Medical Center at Dallas
University of Minnesota Medical
School
Harvard Medical School
University of Pennsylvania School
of Medicine
1999-Present NIH Diabetes
Endocrinology Research Center
Co-Director
1995-1998 National Institutes of
Health, Division of Research Grants
Member, Advisory Committee
2001-2004 NIH Member, Central
Tenure Committee
1997-Present Appointed National
Institutes of Health Senior
Biomedical Research Service
2003-Present Member National
Advisory Council on Aging
2003-Present Member National
Institute of Neurological Disorders
and Stroke
2000-Present NIH/NIDDK Member,
Ad Hoc Strategic Planning Group,
Stem Cells and Developmental
Biology
2000-2004 National Heart, Lung,
and Blood Institute Member,
Advisory Council
1994-1998 National Institutes of
Health Member, Clinical Cancer
Investigation Research Committee
(Committee H)
1994-present National Institutes of
Health Member, Reviewers Reserve
2002 NIH Immunology Study
Section Boundaries Team Member
1995 National Institutes of Health
Grant Reviewer, Molecular Biology
Study Section, Ad Hoc
1999-2002 National Institute on
Aging Member/Steering Committee
for the Alzheimer's Disease Data
Coordinating Center
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Weissman,
Irving L.
Yamada,
Kenneth M.
Stanford University School of
Medicine
National Institute of Dental and
Craniofacial Research, NIH
NIH Stem Cell Task Force Member,
Stem Cell Research Career
Pathways Working Group Member
and 3 Congressional Hearings Held
on Stem Cell and Human Cloning
1996-Present Branch Chief National
Institute of Dental and Craniofacial
Research, Craniofacial
Developmental Biology and
Regeneration Branch, NIH
*Government associations listed in the table only include the latest NIH
appointments/engagements and Congressional hearing appearance.
Overlapping the Commercial and Governmental circles generates the list of people who
are playing active roles in stem cell related commercial activities while maintaining
strong political existence in federal-level policy making processes regarding the stem cell
technology. 10 people are identified to fall into this overlap and listed below in Table 8.
Table 8: Firms, Names and Governmental Affiliations of the People Who Are in the
Overlap of the Commercial and Governmental Circles
Firm Name : Gqvernmeital Affiliation 
1996 National Institutes of Health
working group on Stem Cells and
AaTechnology Atala, Anthony Developmental Biology, and the
National Institutes of Health
Bioengineering Consortium
1998 - 2002 9 Appearance at
West, Michael Senator and CongressionalTechnology Hearings
Hearings
1992-1996 Member of the
Diacrin Sachs, David Immunobiology Study Section at
the National Institutes of Health
1999-2002 Member, National
Geron Corporation Campisi, Judith Advisory Council on Aging,
National Institutes of Health
Member of the Board of ScientificLayton BioSciences Eberwine, James Counselors for the National
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Geron Corporation
Layton BioSciences
Layton BioSciences
StemCells Inc
StemCells Inc
Shay, Jerry
Lee, Virginia
Trojanowski,
John
Gage, Fred
Weissman,
Irving
Institute on Drug Abuse
1994-present National Institutes of
Health Member, Reviewers Reserve
2003-Present Member National
Advisory Council on Aging
1999-2002 National Institute on
Aging Member/Steering Committee
for the Alzheimer's Disease Data
Coordinating Center
1999 NIH Member/Working
Group/Guidelines for Use of
Human ES Cells; 1998-2001 NIH
Member/National Advisory Council
on Aging
NIH Stem Cell Task Force
Member, Stem Cell Research
Career Pathways Working Group
Member and 3 Congressional
Hearings Held on Stem Cell and
Human Cloning
The overlap of the Scientific and Commercial circles reveals stem cell scientists who
keep one foot in business while the other in research. 5 such business academics, listed
in Table 9, are identified within the scope of the 12 sample companies.
Table 9: Information of the Stem Cell Scientists Who Are in the Overlap of the Scientific
and Commercial circles
'... .. ...... " : e .f ': : : N umb er ofFirm :Name- Rol --Affiliation --**:--
·'i' '" 1 -?-.. :. '--:l-e"' "'ers.
StemCells SAB Salk Institute
Inc | Gage, Fred for Biological 21 4Inc Member
Studies
University of
Layton Lee, Founder Pennsylvania 10 2
BioSciences Virginia School of
Medicine
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Geron
Corporation
Layton
BioSciences
StemCells
Inc
Shay, Jerry
Trojanowski
, John
Weissman,
Irving
SAB
Member
Founder
Founder
University of
Texas
Southwestern
Medical
Center at
Dallas
University of
Pennsylvania
School of
Medicine
Stanford
University
School of
Medicine
22
8
19
16
1
7
*Number of patents whose assignees are one or more sample stem cell companies.
**Number of papers co-published by the scientists and one or more sample stem cell
companies.
Finally, the intersection of the above 3 overlaps captures the inner circle this thesis tries
to identify within the scope of the 12 sample firms. People in this "core" are not only
prominent scientists and business entrepreneurs, but also activists in stem cell related
political issues. The 5 inner circle members, as listed in Table 10, happen to cover the
entire roster of the academic businessmen listed in Table 5, who connect the Scientific
and Business domains in the stem cell industry. While the size of this circle seems
small in the context of the sample firms, the result proves the stem cell inner circle does
exist. In the much broader stem cell industry, a larger and more complete inner circle
can be expected.
Table 10: Stem Cell Inner Circle - Scientists from the Sample Stem Cell Firms Who Are
Actively Participate in Scientific, Commercial and Governmental Activities
Name # of # of Governmental.Firm* Name: ' i Role Affiliation
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StemCells
Inc
Layton
BioSciences
Geron
Corporation
Layton
BioSciences
StemCells
Inc
Gage, Fred
Lee,
Virginia
Shay, Jerry
Trojanowski,
John
Weissman,
Irving
SAB
Member
Founder
SAB
Member
Founder
Founder
Salk Institute
for
Biological
Studies
University of
Pennsylvania
School of
Medicine
University of
Texas
Southwestern
Medical
Center at
Dallas
University of
Pennsylvania
School of
Medicine
Stanford
University
School of
Medicine
*Some scientists are with more than one company. The
have latest association with.
21
10
22
8
19
4
2
16
1
7
1999 NIH
Member/Working
Group/Guidelines
for Use of
Human ES Cells;
1998-2001 NIH
Member/National
Advisory Council
on Aging
2003-Present
Member National
Advisory Council
on Aging
1994-present
National
Institutes of
Health Member,
Reviewers
Reserve
1999-2002
National Institute
on Aging
Member/Steering
Committee for
the Alzheimer's
Disease Data
Coordinating
Center
NIH Stem Cell
Task Force
Member, Stem
Cell Research
Career Pathways
Working Group
Member and 3
Congressional
Hearings Held on
Stem Cell and
Human Cloning
listed are the companies they
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5.2 Results Analysis
From the results presented, we can see that in the stem cell industry, there exist a number
of people who play at least two of the following three roles - professor, entrepreneur and
policy advisor, and perform cross-domain functions. A small fraction of those people,
who form the stem cell inner circle, are in fact connecting the scientific, commercial and
governmental worlds by playing critical roles in all of them. But what is the rationale
behind the formation of such a social elite?
Today, many university scientists are neither teachers nor disinterested experts, but a
hybrid - part executive and part researcher - pursuing new and little-understood business
strategies. According to the Association of University Technology Managers, there have
been over 3,000 companies that academics have spun-off over the last 20 years. Like
most academics, those founding scientists have university affiliations and spend most of
their time performing research. What makes them different is by keeping one foot in
business and the other in the universities, these scientist-businessmen get the best from
both worlds - not only do they get early access to hot new discoveries and federally
subsidized laboratory space, but more importantly, they receive approval of colleagues
serving on federal grant-review boards more easily. Such connections are apparently
even more crucial in the stem cell industry where federal research funding is extremely
competitive.
Besides the close relationship with scientific institutions, many stem cell companies
builds or tries to build connections to the government world as well. A tight bond with
the relevant government agencies not only gives stem cell firms a powerful leverage to
influence the stem cell policy making process in favor of their interests and secure more
federal funding directed to the firms' research focus, but also makes would-be private
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investors such as venture capitalists perceive good investment potential in them. The
insider regulatory and legislative information, no matter being positive or negative, give
those firms fast lead time in either commercializing the stem cell products and gaining
the market share or preparing the exit strategy to quit the stem cell industry.
Among the four network mechanisms that define social capital in theory, the brokerage
mechanism can be perfectly applied in the case of stem cell inner circle. In the stem cell
industry, structural holes exist among the scientific, commercial and governmental worlds
where people on either side of the gaps circulate in different flow of information.
Therefore, brokering the flow of information between those different domains should
bring competitive advantage to people whose networks span the holes and the stem cell
companies where those people belong. For instance, the bridge connections of a
company executive who is also a NIH Stem Cell Task Force member provides her with
an edge on information access - she can reach a higher volume of information compared
to people who are solely involved in either commercial or governmental activities,
because she is connected to people across two separate networks that contains fewer
redundant bits of information. Same rationale applies to the bridging behaviors between
the scientific and commercial worlds in the stem cell field. Not only can the
scientist-businessmen have early access to hot new discoveries in universities, as
entrepreneurs, they get access to the real-time market demand for the stem cell
technologies as well, which can then guide their scientific research towards quicker
commercialization. The existence of the cross-finctional inner circle justifies the
application of the brokerage theory to this industry, which in term serves as a perfect
rationale behind the formation of the stem cell inner circle.
The stem cell inner circle that this thesis focuses on, as described in the Methodology
chapter, differs from the traditional inner circle in that it connects three different domains
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in the stem cell field - scientific domain, commercial domain and governmental domain,
rather than just sections along the only business dimension in the traditional inner circle
context. Like the traditional inner circle, interlocking directorships exist in the stem cell
industry and are the key identifier of the stem cell inner circle. Analogous to the
interlocking directorships in social setup for traditional inner circle where a particular
individual sits on two or more corporate boards, interlocking directorships in stem cell
industry represent the simultaneous cross-domain appointments in scientific institutions,
for-profit business corporations and government agencies of an individual. Moreover,
such cross-domain multi-appointments enable all the inner circle members to be
connected to each other. For instance, among the 5 inner circle members identified in
this research, Gage and Weissman are both founders of StemCell, Inc. while Lee and
Trojanowski are not only co-founders of Layton BioSciences, but at the same time,
colleagues in School of Medicine at University of Pennsylvania. Gage and Lee both
served on the National Advisory Council on Aging. Shay holds a membership of
American Aging Association as Weissman does while sharing the advisory responsibility
with Trojanowski in American Federation for Aging Research. The acquaintance with
each other and the appointments in the same organizations certainly lays a solid
foundation for a less divided and better organized stem cell inner circle, which can be
very effective in finding and promoting the shared concerns of its members and
advocating for collective actions. These are the critical causes of the formation of inner
circle as described in Useem's work (1984). And this is especially true in a highly
regulated industry like stem cell where no single firm could easily slacken the rigorous
policy constraints.
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CHAPTER 6: CONCLUSION AND IMPLICATION FOR FUTURE RESEARCH
The study of a carefully selected sampling of 12 firms that are developing neural stem
cell technologies attests to the very existence of a stem cell inner circle which is
composed by people who are playing active roles across the scientific, commercial and
governmental domains in the stem cell field. The members of this circle all assume
interlocking directorships not only in the business world, but in the scientific institutions
and governmental agencies as well. By holding the cross-domain multi-positions, these
members are not only functioning as bridges of information between three somewhat
separate worlds, but also building close connections between each other.
Why such an inner circle emerges could lie in two factors. First of all, the stem cell
industry has seen considerable governmental intervention especially since the use of
human embryos in stem cell research became a heated battleground of ethic debate.
Current stringent public policy fetters the development of stem cell technology in the U.S.
In an emerging industry which demands significant amount of basic research, the
extremely limited government investment drains up the attractiveness of the stem cell
technology and consequently drives away would-be private investors. While no single
firm has the ability to lift or remove the policy constraints, collective action will be an
ideal approach to maximize the voice of the stem cell industry as a whole. In Useem's
work (1984), inner circle members are described to be less divided and better organized
for carrying out collective actions and promoting shared concerns. It makes perfect
sense that the stem cell inner circle emerges during this financial and political hardship to
best advocate for a friendlier political atmosphere around the stem cell research.
However, how the shared visions about collective actions are reached in the circle and
how the inner circle elite actually execute the collection actions are yet to be explored
and can be future topics of research interest.
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Second, members of the stem cell inner circle are all well connected to the scientific,
commercial and governmental worlds through their networks bridging the information
gaps between any two of the three. The social capital theory argues that people who do
better are somehow better connected. Research on brokerage mechanism also asserts
that structural holes create a competitive advantage for individuals whose networks
expand across the holes. So theoretically, besides functioning as a stronger advocate
group for collective action, the stem cell inner circle is also formed to capture the
competitive advantages for its members and their companies. However, whether
involvement in the circle really benefits the relevant stem cell companies financially
remains a big question mark. Therefore, one future research topic associated with the
stem cell inner circle could be to build the quantitative connection between this inner
circle and the stem cell firm performance. This will help answer interesting questions
like whether having more inner circle members in a stem cell company could secure more
venture capital funding or federal research grants. If the answer is yes, it then can be
assumed that recruiting inner circle members would be a smart human capital strategy for
stem cell companies.
Finally, the benefit of having a say in the stem cell regulatory agencies is clear for stem
cell companies. However, the conflict of interest issue is also straightforward. For
scientists who testify in federal-level hearings or advise lawmakers on the science behind
a debated issue, their presence in firms that make profit by commercializing stem cell
technologies and products creates an ethical minefield. Since these supposedly
objective scientists have business interests that overlap with their scientific views, they
can provide scientific advice in line with their financial interests which may be
suboptimal. Is the existence of the stem cell inner circle partially attributed to the fact
that those academic entrepreneurs want to maximize their commercial profits by
influencing the public policy and public opinion to become in favor of their interests?
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To better understand the forming mechanism of this inner circle, further research beyond
empirical study will be required.
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APPENDIX 1: STEM CELL TYPES
1. Embryonic stem cells
Embryonic stem cells (ESCs) are derived from a group of cells called the inner cell mass,
which is part of the 4- to 5-day-old embryos, called the blastocyst and have two
capacities believed to be unique: they are capable of seemingly limitless reproduction,
and they can develop into any type of cell, tissue, or organ as they mature. At the same
time, embryonic stem cells cannot themselves develop into a full organism. Their
ability to replicate themselves indefinitely while remaining in an "undifferentiated" state
means that embryonic stem cells offer a potentially unlimited source of cells for organ
transplantation, and provide a model system for drug discovery and the study of human
development.
Scientists discovered ways to obtain or derive stem cells from early mouse embryos more
than 20 years ago (Evens et al 1981, Martin 1981). However, it wasn't until 1998 that
many years of detailed study of the biology of mouse stem cells led to the discovery of
how to isolate stem cells from human embryos and grow the cells in the laboratory
(Thomason et al 1998, Shamblott et al 1998). The mouse embryonic stem cell can be
easily defined by its ability to contribute to all the tissues of a developing embryo, as
normal mice can be derived from embryonic cells. Among the types of cells derived
from cultured mouse ESCs are fat cells, various brain and nervous system cells,
insulin-producing cells of the pancreas, bone cells, hematopoietic cells, yolk sac,
endothelial cells, primitive endodermal cells, and smooth and striated muscle cells,
including cardiomyocytes-heart muscle cells (Odorico 2001).
However, it is illegal worldwide to derive a human being from human embryonic stem
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cells. Therefore, different terms have to be used to express the experimental definition
of human embryonic stem cell. Human embryonic stem cells are generally derived from
blastocysts that develop from eggs that have been fertilized in vitro - in an in vitro
fertilization clinic - and then donated for research purposes with informed consent of the
donors. In normal embryonic development, embryonic stem cells disappear after the 7th
day and begin to form the three embryonic tissue layers. However, once extracted from
the inner cell mass during the blastocyst stage, embryonic stem cells can be cultured in
the laboratory and under the right conditions will proliferate indefinitely, that is, produce
more cells like themselves and give rise to many different cell types in culture. When
placed back into a developing embryo, they contribute to all of the tissues. So this is
how human embryonic stem cells are defined - as pluripotent cells in tissue culture.
2. Fetal Stem Cells
Fetal stem cells are primitive cell types in the fetus that develop into the various organs of
the body eventually. They are generally harvested from fetuses obtained through
elective abortion. Research with fetal tissue so far has been limited to only a few cell
types: neural stem cells, including neural crest cells; hematopoietic stem cells; and
pancreatic islet progenitors. Neural stem cells, which are numerous in the fetal brain,
can be isolated and grown in an undifferentiated form in culture, and they have been
shown to differentiate into the three main types of brain cells (Brustle et al 1998, Villa et
al 2000). The fetal liver and blood are rich sources of hematopoietic stem cells, which
are responsible for generating multiple cell types in blood, but their properties have not
been extensively investigated. The umbilical cord and placenta are rich sources of
hematopoietic stem cells too, although they are not part of the fetus. Finally, when
transplanted into diabetic mice, tissue extracted from the fetal pancreas has been shown
to stimulate insulin production. However, it is not clear whether this is due to a true
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stem cell, a more mature progenitor cell, or to the presence of fully mature
insulin-producing pancreatic islet cells themselves (Beattie et al 1997).
3. Adult Stem Cell
Adult stem cells are undifferentiated cells found among differentiated cells in a tissue or
organ of the adult body. They can renew themselves in the body, making identical
copies of themselves for the lifetime of the organism, or become specialized to yield the
cell types of the tissue of origin. Unlike embryonic stem cells, which are defined by
their origin (the inner cell mass of the blastocyst), adult stem cells share no such
definitive means of characterization and the origin of adult stem cells in mature tissues is
unknown. Adult stem cells are rare. Their primary roles are to maintain the steady
state functioning of a cell and to replace cells that die because of injury or disease with
limitations.
Almost 40 years ago, the first stem cell type, hematopoietic stem cell, which forms all the
types of blood cells in the body, was discovered in bone marrow and was later identified
responsible for the successes of bone marrow transplants in increasing the survival of
patients with leukemia, inherited blood disorders and disease of the immune system (Till
et al 1961). A few years after the discovery of hematopoietic stem cell, a second
population of stem cells, bone marrow stromal cells, which are mixed cell population that
generates bone, cartilage, fat, and fibrous connective tissue, were also found in the bone
marrow. During the past few years, sources of adult stem cells that have been
mentioned in scientific reports include bone marrow, blood, the eye, brain, skeletal
muscle, dental pulp, liver, skin, the lining of the gastrointestinal tract, and pancreas.
Although the fact that adult stem cells exist is exciting enough, research on adult stem
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cells has recently generated even more excitement, suggesting that at least some adult
stem cells are multipotent. Scientists have found adult stem cells in many more tissues
than they once thought possible, which shows that the potential of adult stem cells does
not seem to be restricted by their source. For example, a series of intriguing
observations indicates that muscle and blood might be developed from stem cells found
in the tissues of either system (Jackson et al 1999, Gussoni 1999). This finding has led
scientists to ponder over the question whether other types of adult stem cells can be used
for transplants as hematopoietic stem cells and moreover, whether they can be used for
transplants to organs and tissues other than those from which they are extracted.
However, since recent findings of adult stem cells are so new and studies of them raise so
many questions, even the most preliminary generalization and conclusions as to
therapeutic potential are tentative and the detailed challenges of the adult stem cell
research will be discussed in the later part of the thesis.
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APPENDIX 2: US STEM CELL FIRMS 12',3
A
Aastrom Biosciences
Acorda Therapeutics
Advanced Cell Technology
Advanced Tissue Sciences
Alexion Pharmaceuticals
Alpha Cord
American Cord Blood Inst
Anthrogenesis Corp
Ariad Pharmaceuticals
Artecel Sciences Inc
B
BioCell
Bioheart Inc
BioLife Solutions
BioTransplant
BirthCells Technology
Boston Life Sciences
C
12 Source: Tissue Engineering and Stem Cell Technology Report 2003 - 2013, VisionGain, 2003
13 Source: Search Report, Biomedical Industry Analyzcr, 2004
83
California Cryobank
Cardion Pharma Inc
CellExSys
Cells for Life Ltd
CorCell
Cord Blood Registry
CORD Inc
Creative BioMolecules
Cryobanks International
Cryo-Cell International
Cue Therapeutics
Curis Inc
CyThera Inc
Cytomatrix LLC
D
Dentigenix
Diacrin Inc
E
Endovasc Ltd Inc
Exten Industries
F
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FamilyLink
G
Genetics Institute
Genzyme Biosurgery
Geron Corp
H
Human Genome Sciences Inc
I
Immunicon
Incara Pharmaceuticals Corp
Infigen Inc
Integra Lifesciences
Isto Technologies
Ixion Biotechnology
K
Kaleidos Pharma
Kensey Nash
L
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Large Scale Biology Corp
Layton Bioscience Inc
Lifebank
Lifecell Inc
M
Macropore Biosurgery Inc
MorphoGen Pharmaceuticals
MultiCell Technologies Inc
N
NeoTherapeutics Inc
Nephros Therapeutics Inc
NeuralStem Biopharmaceuticals Inc
Neuronyx Corp
New England Cord Blood Bank
Newborn Blood Banking Inc
Nexell Therapeutics
0
Oncosis
Orbus Medical Technologies
Organ Recovery Systems
Ortec
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Osiris Therapeutics
P
Paradigm Genetics
Polymerix
PrimeGen Biotech
ProNeuron Biotechnologies
Quark Biotech Inc
R
Regeneron Pharmaceuticals
RegeneRx Biopharmaceuticals
S
Saneron CCEL Therapeutics
Sciperio
Securacell Inc
Selective Genetics
Sertoli Technologies
StemCell Technologies
StemCells Inc
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StemCo Biomedical
StemCyte
StemSource Inc
T
TEI Biosciences
ThermoGenesis
Tissue Transformation Technologies
Titan Pharmaceuticals
V
ViaCell Inc
ViaCord
Vistagen Inc
Vitro Diagnostics Inc
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